Omicron has high immune escape potential: INSACOG

admin
admin December 31, 2021
Updated 2021/12/31 at 2:51 PM

The Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG) reported in its recent bulletin that there is now clear experimental and clinical evidence confirming Omicron’s extremely high immune escape potential, although early estimates indicate the severity of illness being lower than in past outbreaks.

According to INSACOG, appropriate public health measures and investigations are being carried out for Omicron surveillance in India. It also noted that vaccines or prior infection appear to have a significantly reduced ability to protect against symptomatic infection by the Omicron variant globally.

According to INSACOG’s December 29 bulletin, “While Delta remains the most common VOC worldwide, the Omicron variant has entirely supplanted it in southern Africa and is on pace to become the dominant variant in the United Kingdom and elsewhere.”

According to the genomic consortium, there is now clear experimental and clinical evidence confirming Omicron’s extremely high immune escape potential, which seems to be the key component of its growth advantage over Delta, citing worldwide statistics.

However, initial estimates of illness severity have been lower than in prior outbreaks. It stated that “it’s unclear if these preliminary findings can be applied to older non-immune people, and the hazard level remains high.”

The INSACOG reports on the genomic surveillance of SARS CoV-2 throughout the nation using samples from sentinel locations as well as extensive state-by-state district analysis in select states.

According to statistics updated on December 29 by the Union Health Ministry, India has reported 781 cases of the Omicron form of coronavirus throughout 21 states and union territories, with 241 people recovered or migrated.

 

Source: The Hindu

Share this Article
Leave a comment

Leave a Reply

Your email address will not be published.